MERCK & CO INC

20 February, 2025

Investors File Class Action Lawsuits Against Merck & Co. Over Alleged Misleading Claims on Gardasil Vaccine Revenue and Demand

Merck & Co. is facing significant legal challenges as class action lawsuits have been filed by investors who purchased securities between February 3, 2022, and February 3, 2025. The lawsuits assert th...
Read More

19 February, 2025

Investors File Class Action Lawsuit Against Merck & Co. Over Alleged Misleading Information on Gardasil Vaccine Revenue

Merck & Co. is currently facing significant legal challenges, as a class action lawsuit has been filed against the pharmaceutical company by the Rosen Law Firm and Robbins LLP. This lawsuit is on beha...
Read More

18 February, 2025

Merck & Co. Earns High Rating Amid Mixed Q4 Results and Concerns Over Future Growth

Merck & Co. (MRK) is currently generating substantial attention from investors, as evidenced by a strong rating of 90% from Validea’s Earnings Yield Investor model, based on Joel Greenblatt's investme...
Read More

17 February, 2025

Merck & Co. Reports Strong Q4 Earnings Despite Challenges, Faces Stock Decline Following Guidance and HPV Vaccine Shipment Suspension

Merck & Co. recently reported its fourth-quarter earnings, showcasing resilience despite facing challenges in certain markets. With fourth-quarter sales reaching $15.62 billion, a 7% increase year-ove...
Read More